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Exploring the “Thyroid–Skin 
Connection”: Concepts, Questions, 
and Clinical Relevance
Ralf Paus1,2
The “thyroid–skin connection” has become a hot frontier in dermatoendocrinology. 
In this context, the pituitary hormone that controls thyroid hormone production, 
thyrotropin (TSH), caught the attention of skin researchers only after it was reported 
that the receptor for TSH (TSH-R) is transcribed and translated by selected cultured 
human skin cell populations and in normal human scalp skin in situ, introducing 
skin as a nonconventional, peripheral target organ for regulation by TSH. In this 
issue, Cianfarani et al. present corroborating evidence and raise the old question of 
whether intracutaneous TSH-R stimulation by autoantibodies contributes to the skin 
changes seen in autoimmune thyroid disease. This provides a good opportunity to 
define the questions to be addressed when exploring the thyroid–skin connection.
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The long-recognized “thyroid–skin con-
nection“ (Freinkel and Freinkel, 1972; 
Messenger, 2000; Slominski et al., 2002) 
encompasses many layers of complexity; 
the more one explores this connection, 
the more biologically fascinating and 
clinically important questions arise. To 
avoid confusion in this expanding maze 
and to focus on the research frontiers that 
matter most, it helps to define the ques-
tions of highest priority.
Both abnormally low and excessively 
high serum levels of thyroid hormones (THs) 
can alter the appearance and function of 
human skin and its appendages, leading to 
pretibial myxedema and telogen effluvium 
(Freinkel and Freinkel, 1972; Messenger, 
2000; van Beek et al., 2008). Much less 
obvious, however, are the underlying 
mechanisms that cause these changes.
For example, human skin and its 
appendages are known to express TH 
receptors (TRβ1; Billoni et al., 2000), and 
THs are known to alter the expression 
of selected keratins (Ramot et al., 2009). 
But how does one convincingly explain 
why both hypo- and hyperthyroid states 
are associated with substantial hair loss 
(telogen effluvium)? van Beek et al. (2008) 
recently demonstrated that THs can pro-
long the duration of hair growth (anagen 
phase) and that they can stimulate hair 
matrix keratinocyte proliferation, hair pig-
mentation, and even the gene and protein 
expression for selected keratins in serum-
free organ culture (i.e., under “hypothy-
roid” growth conditions). In addition, 
THs stimulate hair growth and promote 
wound healing in mice (Safer et al., 2001, 
2005). Yet it remains unclear how these 
clinically important effects are brought 
about. Thus, even at the most basic level 
of the thyroid–skin connection puzzle, 
we know little about intracutaneous 
TRβ1–TH interactions on the molecular 
level and on the functionally most impor-
tant TRβ1+ cells in skin physiology.
TH production and release by the 
thyroid gland are controlled by the 
hypothalamic–pituitary–thyroid (HPT) 
axis (Figure 1). Within the HPT axis, 
hypothalamic thyrotropin-releasing hor-
mone (TRH) stimulates release of pituitary 
thyrotropin (thyroid-stimulating hormone, 
TSH); TSH then upregulates TH produc-
tion in the thyroid gland, with various 
endocrine feedback loops that maintain 
homeostasis (Larsen et al., 2003). 
With respect to skin, there are three 
major questions. The first is whether pri-
mary HPT-axis abnormalities that alter 
TH serum levels (and thus cause excess 
or insufficient TRβ1 stimulation in human 
skin) are present in a given patient. The 
second, more intriguing, question is 
whether the other key players in the 
central HPT axis alter cutaneous function 
directly via increased or lowered TRH or 
TSH serum levels—assuming that at least 
some cutaneous cell populations express 
functional cognate receptors. The third 
and most provocative question is wheth-
er human skin has a peripheral signaling 
system that exhibits characteristics of the 
central HPT axis.
The first question does not concern us 
here, because this is the classic domain of 
endocrinological diagnosis and therapy 
(Larsen et al., 2003). Answering the sec-
ond question requires the demonstration 
of fully functional peripheral receptors 
for TRH and/or TSH (TRH-Rs and TSH-
Rs, respectively) and the identification of 
cell populations and tissues that express 
TRH-Rs and/or TSH-Rs. Subsequently, the 
functional consequences (and the under-
lying signal transduction mechanisms 
and target genes) following TSH stimula-
tion must be characterized.
In this issue, Cianfarani et al. (2010) 
confirm two earlier reports that TSH-Rs 
are expressed in normal human skin at 
the gene and protein levels (Slominski 
et al., 2002; Bodó et al., 2009) and that 
human skin in normothyroid individu-
als is a direct target of TSH stimulation 
(Bodó et al., 2009). Cianfarani et al. also 
suggest that TSH-R stimulation promotes 
the proliferation of human epidermal 
keratinocytes and dermal fibroblasts. Thus, 
hypothyroid diseases, with their hallmark 
elevation of TSH serum levels, may directly 
impact TSH-R+ cell populations in human 
skin via this “pituitary” neurohormone. 
In fact, we had already shown that, 
under serum-free organ culture condi-
tions, human hair follicles and cultured 
dermal papilla fibroblasts from normal 
female skin respond to TSH stimulation by 
an increase in cAMP and by differential 
gene expression changes (including, 
for example, upregulation of α-smooth 
muscle actin, cytochrome c oxidase 1, 
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connective-tissue growth factor, and ker-
atin 5), although neither hair growth nor 
hair pigmentation is significantly altered 
in vitro (Bodó et al., 2009). Moreover, 
human scalp hair follicles transcribe thy-
roid transcription factor-1 and thyroglob-
ulin (Bodó et al., 2009), two key target 
genes of TSH-R stimulation. Cianfarani 
et al. now add thyro peroxidase to this list 
and confirm the previous report of sodium 
iodide transporter transcription in human 
skin (Slowminski et al., 2002).
The third question challenges research-
ers to determine whether TRH and TSH 
are expressed at the gene and protein 
levels in vivo: does skin really operate as 
a nonclassic, peripheral tissue source for 
these neurohormones? 
This provocative question was first 
proposed in a landmark study published 
in this journal by Slominski and col-
leagues (2002), who reported that several 
HPT axis–related genes (TSHβ, TSH-R, 
and possibly even TRH) are transcribed 
in normal human skin—or at least some 
of its constituent cell populations in vitro. 
If human skin indeed generates key hor-
mones of the HPT axis in vivo, we must 
take into consideration that abnormali-
ties in the cutaneous production of TSH 
and/or TRH could alter thyroid function, 
which in turn would have repercussions 
on skin function.
Interestingly, human scalp hair folli-
cles express both TRH and TRH-R mRNA 
and protein in situ. Also, treatment with 
TRH profoundly stimulates hair shaft 
formation and hair matrix keratinocyte 
proliferation, suppresses apoptosis of hair 
matrix keratinocytes, and prolongs active 
hair growth (anagen) in human hair fol-
licle organ culture (Gaspar et al., 2009). 
Although this observation does not prove 
that human skin has established a periph-
eral HPT-axis equivalent, it firmly places 
another key player of the HPT axis on the 
increasingly crowded stage of the cutane-
ous neuroendocrinology theater. 
These findings raise two additional 
questions: what exactly are the functions 
of intracutaneously generated HPT-axis 
hormones in normal human skin physi-
ology, and are these neuropeptide hor-
mones involved in the pathogenesis of 
selected skin disorders?
Some circumstantial support for the 
hypothesis of an HPT axis in human 
skin may be distilled from the obser-
vation that our integument displays 
fully functional equivalent elements 
of the central hypothalamic–pituitary–
adrenal axis (corticotropin-releasing 
hormone→ACTH→cortisol) (Ito et al., 
2005; Slominski et al., 2000, 2007). 
But in order to demonstrate the exis-
tence of an HPT-axis equivalent within 
normal human skin, it must be demon-
strated that intracutaneous feed-forward 
and feedback regulatory loops, similar 
to those that characterize the central 
HPT axis, operate in human skin in vivo 
(e.g., stimulation of intracutaneous TSH 
expression by TRH and inhibition of TSH 
expression by TH; Larsen et al., 2003) 
(Figure 1). Although we have recently 
obtained preliminary evidence that this 
may be the case, convincing evidence 
has yet to be published.
A major and controversial question 
is the exact location of TSH-R protein 
expression in human skin. In normal 
human scalp skin, we found specific, 
prominent, appropriately controlled, and 
highly reproducible TSH-R protein immu-
noreactivity in situ only within the mes-
enchyme (Bodó et al., 2009). This was in 
line with older studies that had detected 
TSH-R immunoreactivity on dermal 
fibroblasts in patients with autoimmune 
Graves disease (Chang et al., 1994; 
Daumerie et al., 2002), indicating that 
TSH effects on the skin epithelium may be 
mediated indirectly via TSH-R+ intrames-
enchymal cell populations (such as fibro-
blasts) that then secrete signals to which 
the epithelium responds (Bodó et al., 
2009). In contrast, Cianfarani et al. (2010, 
this issue) now report that nonscalp 
human skin expresses TSH-R proteins in 
the epidermis and offer explanations for 
this difference.
The question of which cells express 
functional TSH-R proteins within normal 
human skin requires definitive clarifi-
cation in order to understand how TSH 
impacts human keratinocytes in situ (i.e., 
directly or indirectly). The exact location 
of TSH-R expression may also be impor-
tant in the context of autoimmune thy-
roid disease (AITD), specifically Graves 
disease (Larsen et al., 2003).
Endocrinologists have wondered 
for years how skin alterations—in par-
ticular, the excessive accumulation of 
glycosamino glycans in pretibial dermis—
are brought about in Graves disease and 
long ago pioneered the concept that the 
TSH-R is a common intrathyroidal and 
intracutaneous target autoantigen in 
AITD. Besides indications from mice and 
man that excess glycosaminoglycans 
themselves can modulate hair growth 
(Paus, 1991), TSH-R autoantibodies may 
impact human skin. Tao et al. (1989) were 
the first to obtain the data that led them 
to hypothesize that the serum of Graves 
patients with dermopathy contains anti-
bodies that recognize a component of the 
TSH receptor and thus somehow induce 
pretibial myxedema. Subsequently, 
Heufelder et al. (1993) were the first to 
detect TSH-R mRNA in pretibial der-
mal fibroblasts in Graves disease and 
proposed that the TSH-R might play a 
role in the pathogenesis of the associ-
ated connective-tissue manifestations. 
Subsequently, other authors identified 
TSH-R immunoreactivity in Graves pretib-
ial dermal fibroblasts (Chang et al., 1994; 
Daumerie et al., 2002). Although they do 
not cite and discuss these earlier studies, 
Cianfarani et al. (2010) follow in this line 
of research by demonstrating that affinity-
purified IgG from the serum of Graves 
patients stimulates cAMP accumulation 
in and proliferation by cultured human 
keratinocytes. However, we do not know 
yet whether this actually occurs in vivo.
Clinical Implications
•  In hypothyroid patients with elevated thyrotropin (TSH) serum levels, TSH 
likely can exert direct effects on human skin and its appendages, which 
express functional TSH receptors.
•  Intracutaneously expressed TSH receptors may give rise to antithyroid 
autoimmunity, and vice versa—anti-TSH receptor autoantibodies may 
stimulate intracutaneous TSH receptors.
•  If human skin indeed generates key hormones of the hypothalamic–pituitary–
thyroid axis in vivo, abnormalities in the cutaneous production of TSH and/or 
thyrotropin-releasing hormone might even alter thyroid function.
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In any case, the accumulating body 
of evidence that human skin expresses 
TSH-R, TRH, and TRH-R, as well as so-
called “thyroid-specific” genes (which 
may not be thyroid-specific after all), adds 
yet another level of complexity to the 
thyroid–skin connection. On one hand, 
autoantibodies that stimulate intracutane-
ous TSH-Rs may contribute to the devel-
opment of pretibial myxedema (and even, 
perhaps, to disorders of hair growth and 
structure) in patients with AITD. On the 
other hand, it is tempting to speculate that 
autoimmunity against TSH-Rs in Graves 
disease may develop first against extrathy-
roidal TSH-Rs, such as those expressed in 
human skin, with thyroid gland TSH-Rs 
representing only a secondary target in 
AITD (Slominski et al., 2002).
In this autoimmunity context, the exact 
location of TSH-R expression in human 
skin may be important. Intraepithelially 
expressed TSH-Rs could carry a differ-
ent risk of eliciting clinically relevant 
autoimmune responses compared with 
intramesenchymally expressed TSH-R 
antigens. For example, with its substan-
tial constitutive and inducible expres-
sion of immunosuppressive agents 
such as TGFβ1, α-MSH, and IL-10, its 
UV-induced transformation of trans- to 
cis-urocanic acid and its supposedly 
“tolerogenic” Langerhans cells (Kaneko 
et al., 2008; Mutyambizi et al., 2009; 
Nestle et al., 2009), the epidermis may 
provide a relatively immunosuppressive 
or even tolerogenic tissue milieu, just 
like the immunoprivileged hair follicle 
epithelium (Paus and Nickoloff, 2005; 
Ito et al., 2008; Meyer et al., 2008). 
This could be quite different for TSH-Rs 
expressed in the skin mesenchyme—
i.e., within a tissue milieu where report-
edly “immunogenic” Langerhans cells, 
dermal dendrocytes, and multiple 
proinflammatory mechanisms, includ-
ing recently discovered antigen-specific, 
autoimmunity-promoting mast cell– 
T-cell interactions, abound (Stelekati 
et al., 2009).
Thus, dermal rather than epidermal 
TSH-R protein expression in normal 
human skin could be an Achilles heel 
in the struggle to avoid antithyroid auto-
immunity—a constitutive weak spot in 
our natural protective machinery against 
“horror autoinflammaticus” (Masters 
et al., 2009) that may well contribute to 
the exceptionally high prevalence and 
incidence of AITD.
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Intracutaneous HP(T) axis equivalent Central HPT axis
Scenario A      Cianfarani et al., 2010
Scenario B 
• Human epidermis and dermis (non-scalp) express TSH-R
• Stimulation of TSH-R of epidermal keratinocytes by systemic 
  TSH stimulates keratinocyte proliferation and expression of 
  "thyroid-specific" genes
• Intracutaneous TSH-R may be a target of thyroid autoimmunity
• TSH-R autoantibodies modulate keratinocyte functions
• Human epidermis (scalp) expresses TSH gene and protein, 
  but not TSH-R protein
• Human skin mesenchyme (e.g., papillary dermis, hair follicle 
  connective-tissue tissue sheath, and follicular dermal papilla)
  is the predominant site of TSH-R protein expression
• Human epidermis expresses TRH and TSH on the gene 
  and protein levels in situ
• Both systemic and intracutaneous−generated TSH alter 
  human skin epithelial functions (e.g., keratin expression) 
  primarily via stimulation of the secretion of mediators
  that indirectly modulate epidermal and hair follicle 
  keratinocytes
• TSH stimulates expression of "thyroid-specific" genes 
  in human hair follicles
• TRH stimulates, whereas T3 and T4 inhibit, TSH expression
  in human epidermis in situ
Human skin thus displays key elements of the central HPT axis,
including feed-forward and negative-feedback regulation.
Bodo et al., 2009; Gaspar et al., 2009; 
Bodo et al., personal communication`
`
Figure 1. the “thyroid–skin connection.” HPT, hypothalamus–pituitary–thyroid; T3, tri-iodothyronine; 
T4, thyroxine; TRH; thyrotropin-releasing hormone, TSH-R, thyrotropin receptor.
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Heat shock...what we experience when 
we take a break from writing this com-
mentary and step outdoors into the 
100 degree heat and 100% humidity 
that characterizes this particular North 
Carolina day in the in the middle of 
August. Heat shock...what a bacterium 
experiences when it is shifted from 37 
to 42 oC. It is under the latter conditions 
that the biology of heat shock proteins 
was first described. This family of pro-
teins, including the small heat shock 
protein 27 (HSP27), is induced when 
bacteria are subjected to thermal stress, 
or “heat shock.” HSP27 is so named 
because of the aforementioned property 
and its migration as a protein of molecu-
lar weight 27,000 on SDS-PAGE.
Subsequent to its identification as a 
molecular chaperone that facilitates the 
refolding of heat denatured proteins after 
a thermal stress, HSP27 has been shown 
to have other functions, including roles 
in cell signaling, regulation of the actin 
and intermediate filament cytoskeletons, 
and a potential role in the mechanism of 
pemphigus IgG-induced acantholysis. 
In its role as a chaperone, HSP27 forms 
large oligomeric structures of molecular 
weight up to 800,000, which serve as 
an interface upon which denatured pro-
teins can sample different conformations 
as they find a local free energy minima 
and fold to reform their native structures. 
HSP27 has several phosphorylation sites, 
including ser-15, ser-78, and ser-82. 
Upon phosphorylation, large HSP27 
oligomers dissociate into smaller dim-
ers and tetramers, which regulate various 
cellular processes, including organiza-
tion of the cytoskeleton (Benndorf et al., 
1994; Geum et al., 2002; Panasenko et 
al., 2003; Perng et al., 1999), differen-
tiation (Duverger et al., 2004), and tran-
scriptional activity (Chen et al., 2003; 
Miller et al., 2005).
HSP27 has been implicated in a vari-
ety of pathological processes. For exam-
ple, one variant of Charcot–Marie–Tooth 
disease, in which abnormal aggregation 
of neurofilaments results in neurodegen-
eration, is caused by mutations in HSP27 
(Evgrafov et al., 2004). In the autoim-
mune blistering diseases pemphigus 
vulgaris and pemphigus foliaceus, anti-
desmoglein-3 and anti-desmoglein-1 
autoantibodies, respectively, activate 
intracellular signaling pathways, includ-
ing the p38 MAPK–MAPKAP2–HSP27 
signaling axis (Berkowitz et al., 2005). In 
pemphigus, phosphorylation of HSP27 
has been suggested to be one mecha-
nism by which pathogenic IgG induces 
keratin intermediate filament collapse 
and actin reorganization in the target 
keratinocytes; inhibition of this signal-
ing cascade with p38 inhibitors prevents 
pemphigus IgG-induced cytoskeletal 
changes and blistering in vivo (Berkowitz 
et al., 2008; Berkowitz et al., 2006; Lee 
et al., 2009). Additional roles for HSP27 
include transcriptional regulation. For 
example, HSP27 has been shown to 
bind to estrogen receptors and to down-
regulate estrogen response element tran-
scriptional activity (Chen et al., 2003; 
Miller et al., 2005). HSP27 has also been 
shown to interact directly with, and 
thereby to regulate, p53 transcriptional 
activity (Venkatakrishnan et al., 2008). 
MK2 (MAPKAP2) is likely the major 
HSP27 kinase during stress response, 
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What’s in a Name?:  
Heat Shock Protein 27 and 
Keratinocyte Differentiation
Meryem Bektas1 and David S. Rubenstein1,2
In this issue of the Journal, Robitaille and colleagues present data supporting a role 
for the small heat shock protein (HSP) 27 in keratinocyte terminal differentiation. 
This adds to the growing literature implicating HSP27 as a regulator of biologic 
function beyond thermal stress response.
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